Renal AA amyloidosis: survey of epidemiologic and laboratory data from one nephrology centre
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- amyloid metabolismus MeSH
- amyloidóza diagnóza epidemiologie MeSH
- analýza přežití MeSH
- antirevmatika terapeutické užití MeSH
- chronické selhání ledvin diagnóza epidemiologie MeSH
- dospělí MeSH
- hodnocení rizik MeSH
- imunohistochemie MeSH
- incidence MeSH
- jehlová biopsie MeSH
- kohortové studie MeSH
- kombinovaná farmakoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nefrologie statistika a číselné údaje MeSH
- nefrotický syndrom diagnóza epidemiologie MeSH
- nemoci ledvin diagnóza farmakoterapie epidemiologie MeSH
- neparametrická statistika MeSH
- prednisolon terapeutické užití MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- rozložení podle pohlaví MeSH
- senioři MeSH
- stupeň závažnosti nemoci MeSH
- věkové rozložení MeSH
- vyšetření funkce ledvin MeSH
- zdravotnické přehledy MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika epidemiologie MeSH
- Názvy látek
- amyloid MeSH
- antirevmatika MeSH
- prednisolon MeSH
Renal amyloid involvement results, especially, from AL (primary) or AA (secondary) amyloidosis. The extent of amyloid tissue deposits in the kidneys and the clinical course of amyloidosis not only depend on the type of basic process but also reflect the time of diagnosis and the ability to affect the underlying disease. We analyzed laboratory and clinical data from patients with bioptically proven renal amyloidosis. Renal amyloidosis was found in 99 patients (4.65%) from an overall number of 2,128 renal biopsies (RB) performed in our department during a period of 11 years (from 1995 to 2006). AA amyloidosis was diagnosed in 46 patients. Nephrotic syndrome was diagnosed in 27 patients (59%) with AA amyloidosis; all these patients had different degrees of proteinuria. Impaired renal function was discovered in 24 patients (52%); in three of these patients (6.5%) we had to start renal replacement therapy. Patients were treated with corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biological therapy in various regimens. Nine patients (19.5%) died during the one-year follow-up period; complications such as sepsis and cardiac failure were the leading causes of death. Median survival in the AA group was 54 months. Although for approximately half of patients different treatment regimens can lead to a partial remission or disease stabilization, the prognosis of patients with amyloidosis could be regarded as unsatisfactory.
Zobrazit více v PubMed
Ann Rheum Dis. 2000 Aug;59(8):577-9 PubMed
Biochim Biophys Acta. 2005 Nov 10;1753(1):11-22 PubMed
Lancet. 2001 Jul 7;358(9275):24-9 PubMed
J Biol Chem. 1999 Mar 12;274(11):7172-81 PubMed
Int Urol Nephrol. 2009 Dec;41(4):933-9 PubMed
Am J Hematol. 2005 Aug;79(4):319-28 PubMed
Clin Exp Rheumatol. 1996 Sep-Oct;14(5):537-42 PubMed
Medicine (Baltimore). 1991 Jul;70(4):246-56 PubMed
Baillieres Clin Rheumatol. 1994 Aug;8(3):661-90 PubMed
J Rheumatol. 2008 Jul;35(7):1334-8 PubMed
Virchows Arch. 2002 Feb;440(2):111-122 PubMed
QJM. 2000 Aug;93(8):535-42 PubMed
Arthritis Rheum. 2004 Sep;50(9):2966-9 PubMed
Nephrol Dial Transplant. 2004 Dec;19(12):3040-9 PubMed
Curr Opin Nephrol Hypertens. 2002 Nov;11(6):649-55 PubMed
Clin Chem Lab Med. 1999 Apr;37(4):381-8 PubMed
Proc Natl Acad Sci U S A. 2005 May 3;102(18):6473-7 PubMed
Nephrol Dial Transplant. 2003 Jul;18 Suppl 5:v38-40 PubMed
Nephrol Dial Transplant. 2007 Jun;22(6):1608-18 PubMed
Rheumatology (Oxford). 2004 Apr;43(4):410-5 PubMed
FASEB J. 2004 Nov;18(14):1749-51 PubMed
